Nordic MDS Group Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Stockholm Sweden (1984)

Organization Overview

First Clinical Trial
2007
NCT00761449
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Nordic MDS Group

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Monosomy (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Thrombocytopenia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 6